EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy and Relevant Antibody–Drug Conjugates in Gynecologic Oncology: Recent Advances, Ongoing Challenges, and Future Directions

Ting-Tai Yen iD, Tina Yi-Jin Hsieh, Eugene P Toy

Cancers · 20.07.2026 · 18 (14) · 2342

DOI: 10.3390/cancers18142342 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.07.2026. Verfasst von Ting-Tai Yen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA. Die Arbeit nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors and antibody–drug conjugates have rapidly expanded treatment options for gynecologic malignancies, although the magnitude of benefit varies substantially across tumor types and biomarker-defined populations. This narrative review summarizes the biologic rationale, predictive biomarkers, pivotal clinical trials, regulatory approvals, guideline-supported strategies, and emerging directions for immune checkpoint blockade and antibody–drug conjugates in endometrial, cervical, and ovarian cancers. In endometrial cancer, molecular classification and mismatch repair status have transformed treatment selection, with PD-1 or PD-L1 blockade now integrated into first-line chemoimmunotherapy and recurrent disease management. HER2-directed and TROP-2-directed antibody–drug conjugates are also emerging as biomarker-directed strategies. In cervical cancer, human papillomavirus-driven tumor biology, PD-L1 expression, and tissue factor expression support the use of checkpoint inhibitors, antibody–drug conjugates, and therapeutic vaccine approaches across locally advanced and recurrent or metastatic settings. In ovarian cancer, single-agent checkpoint blockade has shown limited activity in unselected populations, but recent advances include biomarker-selected chemoimmunotherapy in platinum-resistant disease and clinically meaningful activity of folate receptor alpha-directed and HER2-directed antibody–drug conjugates. Across gynecologic cancers, key challenges include refining predictive biomarkers, optimizing sequencing after prior immunotherapy exposure, managing overlapping toxicities, and designing trials that enrich for biologically responsive subgroups. Future progress will depend on integrating molecular classification, immune contexture, ADC target expression, and patient-specific clinical factors into treatment selection.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugatebiomarkerscervical cancerendometrial cancergynecologic cancerhuman epidermal growth factor receptor 2 (HER2)immune checkpoint inhibitorimmunotherapyovarian cancerprogrammed cell death protein 1 (PD-1)

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
  • Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.

ORCID-Profile: Ting-Tai Yen

Zitieren

APA

Yen, T. T., Hsieh, T. Y., & Toy, E. P. (2026). Immunotherapy and Relevant Antibody–Drug Conjugates in Gynecologic Oncology: Recent Advances, Ongoing Challenges, and Future Directions. Cancers, 18(14), 2342. https://doi.org/10.3390/cancers18142342

Vancouver

Yen TT, Hsieh TY, Toy EP. Immunotherapy and Relevant Antibody–Drug Conjugates in Gynecologic Oncology: Recent Advances, Ongoing Challenges, and Future Directions. Cancers. 2026;18(14):2342. doi:10.3390/cancers18142342

BibTeX
@article{Yen2026,
  author = {Yen, Ting-Tai and Hsieh, Tina Yi-Jin and Toy, Eugene P},
  title = {Immunotherapy and Relevant Antibody–Drug Conjugates in Gynecologic Oncology: Recent Advances, Ongoing Challenges, and Future Directions},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2342},
  doi = {10.3390/cancers18142342}
}
Kostenlos starten →